MX2022010664A - Materiales y métodos para modular una respuesta inmunitaria. - Google Patents

Materiales y métodos para modular una respuesta inmunitaria.

Info

Publication number
MX2022010664A
MX2022010664A MX2022010664A MX2022010664A MX2022010664A MX 2022010664 A MX2022010664 A MX 2022010664A MX 2022010664 A MX2022010664 A MX 2022010664A MX 2022010664 A MX2022010664 A MX 2022010664A MX 2022010664 A MX2022010664 A MX 2022010664A
Authority
MX
Mexico
Prior art keywords
methods
antibodies
modulating
materials
immune response
Prior art date
Application number
MX2022010664A
Other languages
English (en)
Inventor
Sanjaya Singh
Rajkumar Ganesan
Iqbal S Grewal
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/031749 external-priority patent/WO2020227457A1/en
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2022010664A publication Critical patent/MX2022010664A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen moléculas anti-TRGV9, tales como anticuerpos anti-TRGV9 o fragmentos de unión al antígeno de estos. También se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos, y métodos para usar los anticuerpos para tratar o prevenir enfermedades.
MX2022010664A 2020-02-27 2021-02-26 Materiales y métodos para modular una respuesta inmunitaria. MX2022010664A (es)

Applications Claiming Priority (46)

Application Number Priority Date Filing Date Title
US202062982505P 2020-02-27 2020-02-27
US202062982492P 2020-02-27 2020-02-27
US202062982535P 2020-02-27 2020-02-27
US202062982525P 2020-02-27 2020-02-27
US202062982602P 2020-02-27 2020-02-27
US202062982669P 2020-02-27 2020-02-27
US202062982469P 2020-02-27 2020-02-27
US202062982462P 2020-02-27 2020-02-27
US202062982548P 2020-02-27 2020-02-27
US202062982591P 2020-02-27 2020-02-27
US202062982664P 2020-02-27 2020-02-27
US202062982574P 2020-02-27 2020-02-27
US202062982374P 2020-02-27 2020-02-27
US202062982478P 2020-02-27 2020-02-27
US202062989010P 2020-03-13 2020-03-13
US202062989002P 2020-03-13 2020-03-13
US202062989042P 2020-03-13 2020-03-13
US202062989075P 2020-03-13 2020-03-13
US202062989006P 2020-03-13 2020-03-13
US202062989052P 2020-03-13 2020-03-13
US202062989027P 2020-03-13 2020-03-13
US202062989024P 2020-03-13 2020-03-13
US202062988996P 2020-03-13 2020-03-13
US202062989068P 2020-03-13 2020-03-13
US202062989018P 2020-03-13 2020-03-13
US202062989057P 2020-03-13 2020-03-13
US202062989045P 2020-03-13 2020-03-13
US202062989036P 2020-03-13 2020-03-13
PCT/US2020/031749 WO2020227457A1 (en) 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity
US202063074937P 2020-09-04 2020-09-04
US202063074946P 2020-09-04 2020-09-04
US202063074749P 2020-09-04 2020-09-04
US202063074854P 2020-09-04 2020-09-04
US202063074893P 2020-09-04 2020-09-04
US202063074962P 2020-09-04 2020-09-04
US202063074700P 2020-09-04 2020-09-04
US202063074839P 2020-09-04 2020-09-04
US202063074735P 2020-09-04 2020-09-04
US202063074655P 2020-09-04 2020-09-04
US202063074925P 2020-09-04 2020-09-04
US202063074759P 2020-09-04 2020-09-04
US202063074903P 2020-09-04 2020-09-04
US202063074676P 2020-09-04 2020-09-04
US202063112475P 2020-11-11 2020-11-11
US202063112462P 2020-11-11 2020-11-11
PCT/US2021/019766 WO2021173896A1 (en) 2020-02-27 2021-02-26 Materials and methods for modulating an immune response

Publications (1)

Publication Number Publication Date
MX2022010664A true MX2022010664A (es) 2022-11-30

Family

ID=77492135

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010664A MX2022010664A (es) 2020-02-27 2021-02-26 Materiales y métodos para modular una respuesta inmunitaria.

Country Status (11)

Country Link
US (1) US20220306739A1 (es)
EP (1) EP4110390A1 (es)
JP (1) JP2023515199A (es)
KR (1) KR20220147631A (es)
CN (1) CN115484981A (es)
AU (1) AU2021225870A1 (es)
CA (1) CA3173268A1 (es)
IL (1) IL295897A (es)
MX (1) MX2022010664A (es)
TW (1) TW202144415A (es)
WO (1) WO2021173896A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12077586B2 (en) 2018-09-19 2024-09-03 LAVA Therapeutics N.V. Bispecific antibodies for use in the treatment of hematological malignancies
MX2021013532A (es) 2019-05-08 2022-02-11 Janssen Biotech Inc Materiales y metodos para modular la inmunidad mediada por celulas t.
IL301242A (en) * 2020-09-11 2023-05-01 Janssen Biotech Inc Multispecific vaccine targeting molecules and their uses
EP4237003A1 (en) 2020-10-28 2023-09-06 Janssen Biotech, Inc. Compositions and methods for modulating delta gamma chain mediated immunity
WO2024085182A1 (ja) * 2022-10-18 2024-04-25 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Ｔ細胞性腫瘍の治療剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002351208A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2010045340A1 (en) * 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Methods of humanizing and affinity-maturing antibodies
WO2018123979A1 (ja) * 2016-12-26 2018-07-05 協和発酵キリン株式会社 ミエリンオリゴデンドロサイト糖タンパク質に結合する抗体
WO2019147735A1 (en) * 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor
CN112912397A (zh) * 2018-05-24 2021-06-04 詹森生物科技公司 抗cd3抗体及其用途
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
MX2021013532A (es) * 2019-05-08 2022-02-11 Janssen Biotech Inc Materiales y metodos para modular la inmunidad mediada por celulas t.
EP4233893A3 (en) * 2020-03-13 2023-09-27 Janssen Biotech, Inc. Materials and methods for binding siglec-3/cd33

Also Published As

Publication number Publication date
TW202144415A (zh) 2021-12-01
US20220306739A1 (en) 2022-09-29
EP4110390A1 (en) 2023-01-04
JP2023515199A (ja) 2023-04-12
KR20220147631A (ko) 2022-11-03
IL295897A (en) 2022-10-01
WO2021173896A8 (en) 2022-10-06
AU2021225870A1 (en) 2022-10-20
CN115484981A (zh) 2022-12-16
WO2021173896A1 (en) 2021-09-02
CA3173268A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
MX2022010664A (es) Materiales y métodos para modular una respuesta inmunitaria.
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
PH12020551907A1 (en) Antagonizing cd73 antibody
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
MX2021013532A (es) Materiales y metodos para modular la inmunidad mediada por celulas t.
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
MX2023002945A (es) Moléculas multiespecíficas con direccionamiento inmunitario y usos de estas.
WO2019217145A8 (en) Anti-dll3 antibodies and uses thereof
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
CR20220505A (es) Anticuerpos anti-phf-tau y usos de estos
MX2024002238A (es) Anticuerpos anti-ccr8 y uso de los mismos.
MX2023002948A (es) Métodos y composiciones para modular la inmunidad mediada por cadena beta.
MX2019014400A (es) Inmunoglobulinas que se unen a adamts.
MX2023011339A (es) Anticuerpos anti-tau y usos de estos.
ZA202110285B (en) Antibodies and methods of use
MX2022013920A (es) Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.
MX2024005336A (es) Composiciones y metodos para la modulacion de inmunidad mediada por cadena beta.
MX2020009507A (es) Anticuerpos de dominio individual que se unen a la neurotoxina del tetanos.
EA202193035A1 (ru) Материалы и способы для модуляции иммунитета, опосредованного т-клетками
EA202092672A1 (ru) Антитела против dll3 и их применения